Trial Profile
A Phase 2 Trial Evaluating Sargramostim in Patients With COVID-19 Associated Acute Hypoxemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Feb 2022
Price :
$35
*
At a glance
- Drugs Sargramostim (Primary) ; Sargramostim (Primary)
- Indications Acute hypoxia; COVID 2019 infections; Hypoxaemia; SARS-CoV-2 acute respiratory disease
- Focus Proof of concept; Therapeutic Use
- Acronyms iLeukPulm
- Sponsors Partner Therapeutics
- 28 Jun 2021 Primary endpoint (Change in oxygenation parameter of P(A-a)O2 gradient by Day 6) has been met as per Partner Therapeutics media release
- 28 Jun 2021 Results published in the Partner Therapeutics media release
- 17 Jun 2021 Status changed from active, no longer recruiting to completed.